	US 12,029,793 B2
	pH low insertion peptide targeted delivery of potent cytotoxic compounds
Yana K. Reshetnyak, Saunderstown, RI (US); Oleg A. Andreev, Saunderstown, RI (US); Anna Moshnikova, Warwick, RI (US); and Donald M. Engelman, New Haven, CT (US)
Assigned to Yale University, New Haven, CT (US); and University of Rhode Island Board of Trustees, Kingston, RI (US)
Filed by University of Rhode Island Board of Trustees, Kingston, RI (US); and Yale University, New Haven, CT (US)
Filed on Jan. 28, 2020, as Appl. No. 16/774,966.
Claims priority of provisional application 62/797,881, filed on Jan. 28, 2019.
Prior Publication US 2020/0237926 A1, Jul. 30, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 47/64 (2017.01); A61K 9/00 (2006.01); A61K 31/4745 (2006.01); A61K 31/5386 (2006.01); A61K 31/7036 (2006.01); A61K 38/12 (2006.01); A61K 47/60 (2017.01); A61P 35/00 (2006.01)

CPC A61K 47/6425 (2017.08) [A61K 9/0014 (2013.01); A61K 9/0034 (2013.01); A61K 31/4745 (2013.01); A61K 31/5386 (2013.01); A61K 31/7036 (2013.01); A61K 38/12 (2013.01); A61K 47/60 (2017.08); A61K 47/6415 (2017.08); A61P 35/00 (2018.01)]

69 Claims

1. A method of killing cells in acidic diseased tissue in a subject, comprising administering to the subject a composition comprising a cytotoxic compound and a pH low insertion peptide, wherein the pH low insertion peptide comprises the sequence ADQDNPWRAYLDLLFPTDTLLLDLLWXA (SEQ ID NO: 2), wherein upper case “X” indicates any amino acid residue or an Azido-containing amino acid.